Cancer Discov. 2023 Nov 1;13(11):2299-2300. doi: 10.1158/2159-8290.CD-NB2023-0071.
Two reports from the phase II TADPOLE trial show the benefit of molecularly targeted therapy in pediatric brain tumors with BRAF mutations. Dabrafenib combined with trametinib was superior to chemotherapy in low-grade gliomas and yielded favorable responses in a single-arm study of high-grade ones, results that highlight the importance of biomarker testing in pediatric glioma care.
II期蝌蚪试验的两份报告显示了分子靶向治疗在患有BRAF突变的小儿脑肿瘤中的益处。在低级别胶质瘤中，达拉非尼联合曲美替尼优于化疗，并且在一项针对高级别胶质瘤的单臂研究中产生了良好的反应，这些结果突出了生物标志物检测在小儿胶质瘤治疗中的重要性。
